MRP、P-gp在非小细胞肺癌中的表达及临床意义

Examination of the Expressions and Clinical Significance of MRP and P-gp in NSCLC

目的 观察多药耐药相关蛋白 (MRP)、P-糖蛋白 (P- gp)在肺癌组织中的表达情况及与临床病理的关系 ,以及 MRP与 P- gp之间的相关性 ,探讨 MRP、P- gp与肺癌患者预后的关系。方法 应用 S- P免疫组化法检测非小细胞肺癌 MRP、P- gp的表达情况。结果 4 2例非小细胞肺癌中 MRP阳性率为 4 5 .2 % ,腺癌 MRP的表达明显高于鳞癌 (P<0 .0 5 )。 P- gp阳性表达率为 4 0 .4 % ,P- gp的表达与组织类型、细胞分化程度、TNM临床分期无关 (P>0 .0 5 )。 MRP、P- gp阴性患者术后 1、3年无病生存期 (DFS)明显高于 MRP、P- gp阳性患者 (P<0 .0 1)。肺癌组织中 P- gp与 MRP的表达具有明显相关性 (P<0 .0 5 )。结论 MRP、P-

Objective To examine the expressions of MRP, P gp in lung cancer tissues, and to study the relationships among MRP, P gp, and the clinical pathology,and the prognosis of patients conditions.Methods In the experiment, 42 cases of paraffin embedded specimens of lung cancer tissues were studied to test how MRP and P gp were expressed by using the S P immunohistochemistry. Results Among the 42 cases, 19 cases had MRP positive in lung cancer tissue (45.2%). The expression of MRP in adeno carcinoma was higher than in squemouscarcinoma (P<0.05). The P gp positive rate was 40.4%, which was not associated with patient’s sex, age, clinical stage, degree of differentiation tumor cells (P>0.05). The patient’s DFS in the negative expression of MRP and P gp was longer than that in the positive expression (P<0.01). P gp and MRP were positively correlated (P<0.05).Conclusion P gp and MRP can be used as the reference index when examining the clinical effects of the chemotherapy and making prognosis of patients with lung cancer.